Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists (NSAs), announced it will host an investor presentation on Oct. 21, 2026, at 9 a.m. EDT. The event will spotlight the company's proprietary NSA candidates: HLP003, in Phase 3 development for the adjunctive treatment of major depressive disorder, and HLP004, in Phase 2 development for generalized anxiety disorder.
The presentation will feature perspectives from key opinion leaders on the evolving depression and anxiety treatment landscape, followed by a question-and-answer session with Helus Pharma executives. A live webcast will be accessible through the company's website, with a replay available after the event. For full details, see the full press release.
Helus Pharma, the commercial operating name of Cybin Inc., was founded in 2019 and is committed to helping minds heal by developing proprietary NSAs—synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. The company's NSAs aim to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions. With class-leading data, Helus Pharma aims to improve the treatment landscape through NSAs that provide durable improvements in mental health.
HLP003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the adjunctive treatment of major depressive disorder. The company also has an extensive research portfolio of investigational NSAs and operates in Canada, the United States, the United Kingdom, and Ireland. For more information, visit www.helus.com.
The announcement is significant for investors and patients alike. Depression and anxiety are among the most prevalent mental health disorders globally, and current treatments often fall short for many individuals. Helus Pharma's NSAs represent a novel approach that could offer new hope. The upcoming presentation provides investors with an opportunity to gain deeper insight into the clinical progress and market potential of HLP003 and HLP004, as well as the broader treatment landscape from key opinion leaders.
As a clinical-stage company, Helus Pharma's success hinges on the outcomes of its trials. Positive data from the Phase 3 program for HLP003 could position the company for regulatory approval and commercialization, potentially transforming the treatment paradigm for major depressive disorder. Similarly, progress with HLP004 in generalized anxiety disorder could address a significant unmet need. The investor presentation may influence market sentiment and investment decisions, making it a key event to watch.
BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences, disseminated the announcement. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which offers access to wire solutions via InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and tailored corporate communications solutions. For more information, visit BioMedWire.
